Premium
No association between pre‐diagnostic plasma C‐reactive protein concentration and subsequent prostate cancer
Author(s) -
Platz Elizabeth A.,
De Marzo Angelo M.,
Erlinger Thomas P.,
Rifai Nader,
Visvanathan Kala,
Hoffman Sandra C.,
Helzlsouer Kathy J.
Publication year - 2003
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10368
Subject(s) - prostate cancer , medicine , prostate , prostate disease , oncology , cancer , pathology , endocrinology
BACKGROUND We evaluated the association of pre‐diagnostic plasma concentration of C‐reactive protein, a sensitive, but non‐specific indicator of inflammation, with subsequent risk of prostate cancer. METHODS Included were 264 histologically confirmed prostate cancer cases and 264 age‐matched controls who were participants in the CLUE II cohort of Washington County, MD. C‐reactive protein was measured using a high‐sensitivity immunoturbidimetric assay. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated from conditional logistic regression models by fourth of the C‐reactive protein distribution with cutpoints based on the controls. The median concentrations from the lowest to highest fourth were 0.41, 1.03, 1.90, and 4.53 mg/L. RESULTS Geometric mean plasma concentrations did not differ between the cases (1.24 ± 2.94 mg/L) and controls (1.41 ± 2.97 mg/L; P = 0.16). Compared to the bottom fourth, the ORs (95% CI) of prostate cancer were 1.29 (0.80–2.08), 0.98 (0.61–1.58), and 0.95 (0.57–1.58) for the second, third, and highest fourths ( P trend = 0.66). These findings were unchanged after adjusting for body mass index (BMI) and cigarette smoking status or after excluding men with markedly elevated C‐reactive protein, cases diagnosed during the first 2 years of follow‐up, or controls who never had a PSA test. These findings did not differ by stage or grade of prostate cancer. CONCLUSIONS Pre‐diagnostic plasma concentration of C‐reactive protein was not associated with subsequent risk of prostate cancer. © 2004 Wiley‐Liss, Inc.